Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Clene, retaining the price target of $31.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Clene’s promising preclinical data for their CNM-Au8 treatment. The recent study, funded by the Michael J. Fox Foundation, highlights CNM-Au8’s potential efficacy in treating Parkinson’s Disease (PD) by demonstrating its ability to enhance mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize gene expression in both familial and sporadic forms of PD.
These findings are further supported by results from the Phase 2 REPAIR-PD clinical trial, which showed improved brain energy metabolism markers in PD patients. The integrative analysis of this trial, alongside the REPAIR-MS trial, provides a strong foundation for the continued clinical development of CNM-Au8, reinforcing Pantginis’s confidence in the stock’s potential growth and justifying the Buy rating.
According to TipRanks, Pantginis is an analyst with an average return of -6.1% and a 40.28% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Krystal Biotech, and Travere Therapeutics.